57 related articles for article (PubMed ID: 18353621)
21. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
22. Potential role of anti-VEGF targeted therapies in cervical artery dissection: A case report.
Bonnet C; Sibon I
Rev Neurol (Paris); 2015 Sep; 171(8-9):677-9. PubMed ID: 25912472
[No Abstract] [Full Text] [Related]
23. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
Miksad RA; Lai KC; Stein MC; Healy ME; Rojas R; Krajewski KM; Zhu AX
J Gastrointest Cancer; 2009; 40(3-4):119-22. PubMed ID: 19894033
[No Abstract] [Full Text] [Related]
24. Gastro-pleuro-pericardial fistula following combined radiation and chemotherapy for lung metastases from renal cell carcinoma: report of a case.
Neri A; Lambert Y; Marrelli D; Di Mare G; Mastrogiacomo D; Corso G; Volterrani L; Roviello F
Surg Today; 2013 Dec; 43(12):1457-60. PubMed ID: 23307297
[TBL] [Abstract][Full Text] [Related]
25. [Side effect management of tyrosine kinase inhibitors in urology : Hypertension].
Sikic D; Meidenbauer N; Lieb V; Keck B
Urologe A; 2016 Jul; 55(7):952-5. PubMed ID: 27146871
[TBL] [Abstract][Full Text] [Related]
26. Cardiac toxicity of sunitinib.
Joensuu H
Lancet; 2007 Dec; 370(9604):1978-80. PubMed ID: 18083385
[No Abstract] [Full Text] [Related]
27. Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Lightowlers SV; Greef B; Eisen T; Matakidou A; Fife K; Cameron EA
Ann Oncol; 2019 Jan; 30(1):150-151. PubMed ID: 30358823
[No Abstract] [Full Text] [Related]
28. Reduction in thyroid perfusion after bevacizumab treatment.
van der Veldt AA; Lammertsma AA; Smit EF
Thyroid; 2013 Oct; 23(10):1329-30. PubMed ID: 23548042
[No Abstract] [Full Text] [Related]
29. The role of tyrosine kinase inhibitors (TKIs) as adjuvant treatment for renal cancer. Where do we stand today?
Fragkoulis C; Papadopoulos G; Gkialas I; Ntoumas K
J BUON; 2017; 22(6):1608-1610. PubMed ID: 29332367
[No Abstract] [Full Text] [Related]
30. [Adverse effects of Sutent(®): pseudoporphyria and scrotal necrosis].
Schmutz JL
Ann Dermatol Venereol; 2014 Dec; 141(12):815-6. PubMed ID: 25433941
[No Abstract] [Full Text] [Related]
31. Registration trials in countries without access to US standards of care - pitfalls of interpretation.
Strohbehn GW; Goldstein DA
Nat Rev Clin Oncol; 2021 Jul; 18(7):395-396. PubMed ID: 33833435
[No Abstract] [Full Text] [Related]
32. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
Hartmann JT; Kanz L
Arch Dermatol; 2008 Nov; 144(11):1525-6. PubMed ID: 19015436
[No Abstract] [Full Text] [Related]
33. Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present).
Leonetti A; Zielli T; Buti S
Future Oncol; 2018 Sep; 14(22):2223-2224. PubMed ID: 30064274
[No Abstract] [Full Text] [Related]
34. [Corneal perforations in patients on tyrosine kinase inhibitors].
Amar J; El Kaim P; Scemla B; Boumendil J; Chotard G; Gabison E; Bouheraoua N
J Fr Ophtalmol; 2023 Nov; 46(9):1111-1113. PubMed ID: 37357065
[No Abstract] [Full Text] [Related]
35. [Mechanism analyses and mechanism-based prediction for adverse drug reactions using systems pharmacology].
Kariya Y; Honma M; Suzuki H
Nihon Yakurigaku Zasshi; 2016 Feb; 147(2):89-94. PubMed ID: 26860648
[No Abstract] [Full Text] [Related]
36. Anticoagulation-induced epistaxis.
al-Saden P
Nursing; 1994 Dec; 24(12):33. PubMed ID: 7854724
[No Abstract] [Full Text] [Related]
37. A short report on article by V. Pruliere-Escabasse et al., vol. 27: 285-286, 2009.
Davidson TM
Invest New Drugs; 2012 Feb; 30(1):423; author reply 424. PubMed ID: 20440635
[No Abstract] [Full Text] [Related]
38. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.
Walraven M; Homs MYV; van der Veldt AAM; Dekker H; Koldenhof J; Honeywell R; Barendrecht A; Sebastian SAE; Parr N; Koekman AC; Voest EE; Roest M; Korporaal SJA; Verheul HMW
Angiogenesis; 2018 May; 21(2):325-334. PubMed ID: 29532289
[TBL] [Abstract][Full Text] [Related]
39. Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib.
Iavarone M; Primignani M; Vavassori S; Sangiovanni A; La Mura V; Romeo R; Colombo M
United European Gastroenterol J; 2016 Jun; 4(3):363-70. PubMed ID: 27403302
[TBL] [Abstract][Full Text] [Related]
40. Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib.
Li ZY; Fan XX; Wang YJ; Yao K; Liu ZW; Pan WT; Ye YL; Yang P; Huang YC; Wu ZM; Zhou FJ
Oncotarget; 2016 Jun; 7(23):35181-7. PubMed ID: 27174916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
